secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-TECHNE Corp (TECH)
CIK:        0000842023
Form:       8-K
Filed at:   2023-02-02T23:59:59+00:00
Accession:  0001558370-23-000758
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Techne Q2 FY2023: organic revenue up 4% to $271.6M; GAAP EPS $0.31 vs $0.49 YoY
--------------------------------------------------------------------------------

- Organic revenue grew 4% to $271.6M; reported revenue up 1%.
- GAAP EPS $0.31, down from $0.49; adjusted EPS $0.47, flat YoY (FX headwind $0.02).
- ExoDx Prostate test revenue more than doubled YoY; fourth consecutive record quarter.
- Board declared $0.08/share quarterly dividend, payable Feb 27 to holders of record Feb 13.
- Record GMP protein sales and launch of RNAscope Plus and MauriceFlex instrument.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/842023/000155837023000758/0001558370-23-000758-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/842023/000155837023000758/tmb-20230202x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-000758

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer